Impact of Herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome

BMC Infectious Diseases

Yazdan Yazdanpanah³  Eric Senneville²  Hugues Georges⁴  Hugues Melliez²  Anny Dewilde¹  Karen Champenois³  Julien Poissy² 

[1] Laboratoire de Virologie, CHRU de Lille, France;Service universitaire de Maladies infectieuses et du Voyageur, Centre hospitalier de Tourcoing, France;Equipe ATIP/Avenir INSERM U995, Université Lille Nord de France, Lille, France;Service de Réanimation polyvalente et des Maladies infectieuses, Centre hospitalier de Tourcoing, France

关键词: Viral load;    Neurological/brain;    Prognosis;    Herpes virus;   

Others  :  1158691
DOI  :  10.1186/1471-2334-12-356

 received in 2012-06-07, accepted in 2012-12-14,  发布年份 2012

【 摘 要 】

Background

Herpes simplex encephalitis (HSE) often leads to severe disability or death. Factors usually associated with outcome include Simplified Acute Physiology Score, age and delay of initiation of acyclovir treatment.

Our aim was to determine the impact of Herpes simplex virus (HSV) load in cerebrospinal fluid (CSF) upon HSE outcome.

Methods

We retrospectively determined HSV load in the CSF of 43 patients with confirmed HSE, hospitalized in northern France from 1998 to 2005, using CSF samples collected the day of hospital admission and stored at −20°C. We analyzed the association between HSV load and mortality/morbidity by the Glasgow Outcome Scale. Fisher’s exact test and Wilcoxon’s test were used for statistical analysis.

Results

The M/F sex ratio was 1.7 and median patient age was 61 years. Median HSV load in CSF was 2.0 log copies/μL (IQR 25-75=1.2-2.6). The mortality rate was 32.6% six months after HSE diagnosis. Higher age was associated with mortality (p=0.03). Longer delay in acyclovir initiation tended to be associated with higher mortality but did not reach statistical significance (p=0.08). Severe disability and death due to HSV were associated with a higher Knaus score (p=0.004), later acyclovir initiation (p=0.006), older age (p=0.04) and presence of red blood cells in CSF (p=0.05). HSV load in CSF was neither associated with mortality (p=1.00) nor with morbidity (p=0.90).

Conclusion

In this study, HSV load in CSF was not found to be associated with poor outcome in patients with HSE. These data do not support measurement of HSV load at admission in patients with HSE.

【 授权许可】

   
2012 Poissy et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Whitley RJ: Viral encephalitis. N Engl J Med 1990, 323(4):242-250.
• [2]Whitley RJ: Herpes simplex encephalitis: adolescents and adults. Antiviral Res 2006, 71(2–3):141-148.
• [3]Gordon B, Selnes OA, Hart J Jr, Hanley DF, Whitley RJ: Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol 1990, 47(6):646-647.
• [4]Kapur N, Barker S, Burrows EH, Ellison D, Brice J, Illis LS, Scholey K, Colbourn C, Wilson B, Loates M: Herpes simplex encephalitis: long term magnetic resonance imaging and neuropsychological profile. J Neurol Neurosurg Psychiatry 1994, 57(11):1334-1342.
• [5]Raschilas F, Wolff M, Delatour F, Chaffaut C, De Broucker T, Chevret S, Lebon P, Canton P, Rozenberg F: Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis 2002, 35(3):254-260.
• [6]Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ, Soong SJ: Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986, 314(3):144-149.
• [7]Nahmias AJ, Whitley RJ, Visintine AN, Takei Y, Alford CA Jr: Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis 1982, 145(6):829-836.
• [8]Domingues RB, Lakeman FD, Mayo MS, Whitley RJ: Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol 1998, 36(8):2229-2234.
• [9]Revello MG, Baldanti F, Sarasini A, Zella D, Zavattoni M, Gerna G: Quantitation of herpes simplex virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis by the polymerase chain reaction. Clin Diagn Virol 1997, 7(3):183-191.
• [10]Wildemann B, Ehrhart K, Storch-Hagenlocher B, Meyding-Lamade U, Steinvorth S, Hacke W, Haas J: Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis. Neurology 1997, 48(5):1341-1346.
• [11]Ruzek D, Piskunova N, Zampachova E: High variability in viral load in cerebrospinal fluid from patients with herpes simplex and varicella-zoster infections of the central nervous system. Clin Microbiol Infect 2007, 13(12):1217-1219.
• [12]Jennett B, Bond M: Assessment of outcome after severe brain damage. Lancet 1975, 1(7905):480-484.
• [13]Teasdale G, Jennett B: Assessment of coma and impaired consciousness. A practical scale. Lancet 1974, 2(7872):81-84.
• [14]Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE: APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981, 9(8):591-597.
• [15]Mac Cabe W, Jackson W: Gram negative bacteriema: etiology and ecology. Arch Intern Med 1962, 110:83-91.
• [16]Poissy J, Wolff M, Dewilde A, Rozenberg F, Raschilas F, Blas M, Georges H, Chaffaut C, Yazdanpanah Y: Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis. Clin Microbiol Infect 2009, 15(6):560-564.
• [17]Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, et al.: A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991, 324(7):444-449.
• [18]Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA: Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med 1977, 297(6):289-294.
• [19]Hjalmarsson A, Granath F, Forsgren M, Brytting M, Blomqvist P, Skoldenberg B: Prognostic value of intrathecal antibody production and DNA viral load in cerebrospinal fluid of patients with herpes simplex encephalitis. J Neurol 2009, 256(8):1243-1251.
• [20]Kamei S, Takasu T, Morishima T, Mizutani T: Serial changes of intrathecal viral loads evaluated by chemiluminescence assay and nested PCR with aciclovir treatment in herpes simplex virus encephalitis. Intern Med 2004, 43(9):796-801.
• [21]Schloss L, Falk KI, Skoog E, Brytting M, Linde A, Aurelius E: Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real-time PCR in patients with herpes simplex encephalitis. J Med Virol 2009, 81(8):1432-1437.
• [22]Kurt-Jones EA, Belko J, Yu C, Newburger PE, Wang J, Chan M, Knipe DM, Finberg RW: The role of toll-like receptors in herpes simplex infection in neonates. J Infect Dis 2005, 191(5):746-748.
• [23]Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, Arnold MM, Knipe DM, Finberg RW: Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A 2004, 101(5):1315-1320.
• [24]Jerome KR, Huang ML, Wald A, Selke S, Corey L: Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002, 40(7):2609-2611.